Search results Search for: Search Refine your results by duration: Any Under 5 mins Under 20 mins Over 20 mins Sort by: Relevance Views Date LESSONS & BENEFITS GAINED FROM THE IMPLEMENTATION OF AN AUTOMATED BET SOLUTION Dennis Wong Global at AstraZeneca Liverpool UK and Jordi Iglesias at Charles River The webinar will provide an insight into a global deployment program for an automated solution for Endotoxin testing. A range of implementation aspect... 3 months ago | 74 mins Material Requirements to Support Gene Therapy Development Clare Blue, Director of Analytical Development at Biogen and James Wilkinson, VP of Sales and Customer Success at Refeyn Manufacturing processes for gene therapy products are generally low yielding compared to production processes for other biologics. The material requir... 1 year ago | 73 mins Qualification of Raw Materials Used in the Manufacturing of Cellular Therapies Jim Richardson, Sr Scientific Liaison at USP and Horst Ruppach, Ph.D. Scientific Director at Charles River Presented by Jim Richardson, Sr Scientific Liaison at United States Pharmacopeia Dr. Richardson works in the standards pipeline development group wit... 3 years ago | 79 mins Common Challenges to Overcome While Conducting BSL2 Studies Stephene Rose, MBM, James Justen, BS, Keith Nelson, PhD, DVM, DACVP,Joseph Hampel, DVM, DACLAM Preclinical laboratories face several challenges when conducting animal studies requiring Biosafety Level (BSL) 2 level containment. Some of these cha... 6 years ago | 58 mins Qualification of Raw Materials Used in the Manufacturing of Cellular Therapies Jim Richardson, Sr Scientific Liaison at USP and Horst Ruppach, Ph.D. Scientific Director at Charles River Presented by Jim Richardson, Sr Scientific Liaison at United States Pharmacopeia Dr. Richardson works in the standards pipeline development group wit... 4 years ago | 80 mins Viral Safety by Design for Cell and Gene Therapy Products Mark Plavsic, Chief Technology Officer at Lysogene & Archie Lovatt, Life Sciences Biosafety Scientific Director at SGS Together with product efficacy, product safety is an essential characteristic of any medicinal product including cell and gene therapy (C>) biologic... 4 years ago | 68 mins Viral Safety by Design for Cell and Gene Therapy Products Mark Plavsic, Chief Technology Officer at Lysogene & Archie Lovatt, Life Sciences Biosafety Scientific Director at SGS Together with product efficacy, product safety is an essential characteristic of any medicinal product including cell and gene therapy (C>) biologic... 4 years ago | 67 mins
